Jeil Pharmaceutical Co Ltd (271980) - Total Assets
Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) holds total assets worth ₩501.66 Billion KRW (≈ $339.97 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 271980 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Jeil Pharmaceutical Co Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Jeil Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Jeil Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Jeil Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jeil Pharmaceutical Co Ltd's total assets of ₩501.66 Billion consist of 65.3% current assets and 34.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.2% |
| Accounts Receivable | ₩160.47 Billion | 30.5% |
| Inventory | ₩104.43 Billion | 19.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩13.37 Billion | 2.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Jeil Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jeil Pharmaceutical Co Ltd (271980) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jeil Pharmaceutical Co Ltd's current assets represent 65.3% of total assets in 2024, a decrease from 72.2% in 2017.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2024, up from 3.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 30.5% of total assets.
Jeil Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jeil Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Jeil Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 1.09 | 1.27 |
| Quick Ratio | 0.88 | 0.71 | 0.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩71.17 Billion | ₩27.76 Billion | ₩59.45 Billion |
Jeil Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jeil Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.05 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 7.9% |
| Total Assets | ₩525.70 Billion |
| Market Capitalization | $105.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jeil Pharmaceutical Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jeil Pharmaceutical Co Ltd's assets grew by 7.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jeil Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total assets of Jeil Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩525.70 Billion ≈ $356.26 Million |
+7.87% |
| 2023-12-31 | ₩487.33 Billion ≈ $330.25 Million |
+6.66% |
| 2022-12-31 | ₩456.89 Billion ≈ $309.63 Million |
+7.13% |
| 2021-12-31 | ₩426.49 Billion ≈ $289.02 Million |
+4.11% |
| 2020-12-31 | ₩409.66 Billion ≈ $277.62 Million |
+2.01% |
| 2019-12-31 | ₩401.59 Billion ≈ $272.15 Million |
-0.33% |
| 2018-12-31 | ₩402.90 Billion ≈ $273.04 Million |
-2.62% |
| 2017-12-31 | ₩413.73 Billion ≈ $280.38 Million |
-- |
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more